The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Shhh….Tomorrow’s Market Secrets – Delivered Today
Market Briefing As we begin a critical stretch in the second full week of May, traders are navigating a landscape…
Trump fails to overturn E. Jean Carroll’s $83 million verdict
By Jonathan Stempel NEW YORK (Reuters) – A federal appeals court on Monday refused to throw out an $83.3 million…
Chevron Reveals $16B Of 2024 Capex Budget
Upstream spending in 2024 is expected to be about $14 billion. Downstream capex is expected to be roughly $1.5 billion, with 80 percent allocated to…